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Background: Atrial ﬁbrillation is the most common sustained arrhythmia in the elderly. Serum potassium is
associated with ventricular arrhythmias and cardiac arrest. Little is known about the association of serum
potassium with atrial ﬁbrillation. The objective of this study was to investigate the association of serum
potassium and the risk of atrial ﬁbrillation in a population based setting.
Methods: The study was performed within the prospective population-based Rotterdam Study. The study
population consisted of 4059 participants without atrial ﬁbrillation at baseline for whom baseline levels
of serum potassium were measured. Atrial ﬁbrillation was ascertained from centre visit ECG assessments
as well as medical records.
Results: During a mean follow up of 11.8 years (SD = 5.2 yr), 474 participants developed atrial ﬁbrillation.
Participants with hypokalemia (b3.5 mmol/l) had a higher risk of atrial ﬁbrillation (HR: 1.63, 95%CI: 1.03–2.56)
than those with normokalemia (3.5–5.0 mmol/l). This association was independent of age, sex, serum
magnesium, and other potential confounders. Especially in participants with a history of myocardial infarction,
those with hypokalemia had a higher risk of atrial ﬁbrillation than those with normokalemia (HR: 3.81,
95%-CI: 1.51–9.61).
Conclusions: In this study low serum levels of potassium were associated with a higher risk of atrial ﬁbrillation.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atrial ﬁbrillation is the most common sustained arrhythmia in the
elderly. Atrial ﬁbrillation is associated with a 3 to 5 times higher risk
of stroke [1], and with a higher risk of heart failure, cardiac mortality,
and total mortality [2,3]. Serum potassium, especially hypokalemia
(b3.5 mmol/l), is suggested to be associated with a higher risk of car-
diovascular disease, especially ventricular arrhythmias and cardiac ar-
rest [4]. Few studies previously investigated the association of serum
potassium with the risk of atrial ﬁbrillation [5–8].Clinical studies
showed that lower serum potassium levels were associated with a
higher perioperative risk of atrial ﬁbrillation [5,8]. However, studies
on other populations did not show such an association [6,7]. One
study in haemodialysis patients found low serum potassium to be
associated with an increase in P-wave duration, a marker of atriallogy, Erasmus Medical Center,
ds. Tel.: +31 10 7044294;
r).
td. All rights reserved.conduction [9]. P-wave duration increase has been associated with a
higher risk of atrial ﬁbrillation [10–14]. This supports the hypothesis
that serum potassium is involved in atrial conduction, and possibly
atrial ﬁbrillation. However, as results from clinical studies may not be
generalizable to the general population, results from a population-
based cohort study with a large sample size are relevant.
Therefore, the objective of this study was to investigate the asso-
ciation of serum potassium with the risk of atrial ﬁbrillation in a
population-based setting of community-dwelling elderly.
2. Methods
2.1. Study population
The current study was performed within the Rotterdam Study, a population-based
prospective cohort study, designed to examine the onset of, and risk factors for disease
in older adults, which startedwith a baseline visit between 1990 and 1993 [15]. All partic-
ipants aged 55 years and over in the Ommoord district of Rotterdam, The Netherlands,
were invited (n = 10,275). Of them 7983 (78%) participated in the study. At baseline,
participants were interviewed at home and were examined at the research center,
which included a 10 s, 12-lead resting electrocardiogram (ECG). From that visit onward,
participantswere followed continuously and re-examined at three follow-up examination
rounds (1993–1995, 1997–1999 and 2002–2004). In addition, information on the
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collaboration with the general practitioners in the study area. General practi-
tioners in The Netherlands have a central position in the Dutch health care system.
They register all diagnoses available from their own work and the work from phy-
sicians in the hospital and the outpatient clinic. The medical ethics committee of
the Erasmus Medical Center, Rotterdam, approved the study, and all participants
gave informed consent. The authors of this manuscript have certiﬁed that they
comply with the Principles of Ethical Publishing in the International Journal of
Cardiology.2.2. Serum potassium assessment
At baseline of the study, blood samples were drawn by venapuncture from non-
fasting participants and collected in 5-ml tubes containing 0.5 ml sodium citrate solution.
All tubeswere stored on ice before and after blood sampling. Serumpotassium levelswere
measuredwithin our clinical chemistry department using standardmethods, expressed as
mmol/l. Serum potassiumwas only assessed at baseline of the study, not during follow-up
research center visits.Table 1
Baseline characteristics (n = 4059).
Total sample
(n = 4059)
Hypokalemia
(n = 108)
Normokalemia
(n = 3933)
Hyperkalemia
(n = 18)
Age (years) 69.2(8.6) 70.9(8.6) 69.2(8.6) 77.7(8.7)⁎
Sex (female) 2425(59.7) 85(78.7)⁎ 2394(60.9) 12(66.7)2.3. Assessment of atrial ﬁbrillation
Prevalent and incident atrial ﬁbrillation was ascertained using three methods
[16]. We used ECGs that were obtained at baseline and during follow-up examina-
tions. All ECGs were processed by the Modular ECG Analysis System (MEANS)
which has a very high sensitivity and speciﬁcity for arrhythmias (96.6% and 99.5%,
respectively) [17,18]. To verify the diagnosis of atrial ﬁbrillation, all ECGs with a
MEANS diagnosis of atrial ﬁbrillation, atrial ﬂutter, or any other rhythm disorder
were recoded independently by 2 research physicians who were blinded to the
MEANS diagnosis. The judgment of a cardiologist was taken as decisive in those
cases in which disagreement persisted between the coding physicians. Additionally,
all medical information of all study participants was obtained from general practi-
tioners. In the Dutch health care system, patients have one general practitioner,
who has a gatekeeper function, and this medical information therefore includes a reg-
istration and ﬁling of medical information from their own work as well as the results
from other physicians practicing in hospitals and outpatient clinics. Patients were
only considered as a case of atrial ﬁbrillation if the diagnosis by a medical specialist
or by a general practitioner was ascertained with an ECG. Finally, information was
obtained from a national registration of all hospital discharge diagnoses. Atrial ﬁbril-
lation occurring during a serious disease resulting in death, during myocardial infarc-
tion or during cardiac operative procedures of patients who recovered during the
hospital admission was not included as cases. We did not distinguish between atrial
ﬁbrillation and atrial ﬂutter when we identiﬁed cases because both conditions are
very similar with respect to risk factors and consequences [19,20].SBP (mmHg) 139(22) 147(23)⁎ 139(22) 141(34)
DBP (mmHg) 74(11) 78(12)⁎ 73(11) 72(16)
Blood pressure
lowering drugs:
- ACE inhibitors 200(4.9) 5(4.6) 192(4.9) 3(16.7)⁎
- High ceiling
diuretics
160(3.9) 7(6.5) 151(3.8) 2(11.1)
- Low ceiling diuretics 462(11.4) 61(56.5)⁎ 399(10.1) 2(11.1)
- Beta-blockers 583(14.4) 25(23.1)⁎ 553(14.1) 5(27.8)
- Other 135(3.3) 5 (4.6) 130(3.3) 0(0)
Body mass index
(kg/m2)
26.4(3.7) 26.7(3.8) 26.4(3.7) 26.0(3.5)
Total cholesterol
(mmol/l)
6.7(1.2) 6.5(1.3)⁎ 6.7(1.2) 6.9(1.3)
HDL cholesterol
(mmol/l)
1.3(0.4) 1.4(0.4) 1.3(0.4) 1.1(0.3)⁎
Current smoker 979(24.1) 13(12.0)⁎ 961(24.4) 5(27.8)
Past smoker 1634(40.3) 33(30.6) 1596(40.6) 5(27.8)
History of myocardial
infarction
490(12.1) 14(13.0) 473(12.0) 3(16.7)
Presence of heart
failure
97(2.4) 3(2.8) 91(2.3) 3(16.7)⁎
Presence of diabetes
mellitus
415(10.2) 14(13.0) 395(10.0) 6(33.3)⁎
P-wave duration 119.6(13.5) 123.3(13.8)⁎ 119.5(13.5) 122.7(15.6)2.4. Covariable assessment
Age at baseline and sex were included in all analyses. Body mass index (BMI)
was calculated by dividing weight in kilograms by squared height in meters. Blood
pressure was measured twice at the right upper arm with a random zero mercury
sphygmomanometer in the sitting position. Systolic and diastolic blood pressure
was calculated as the average of the two consecutive measurements. Serum total
cholesterol and high-density lipoprotein (HDL) cholesterol levels were measured
with an automated enzymatic method. Data on medication use were obtained during
the home interview by copying the labels of all the medication used. Information on
smoking status was acquired from a questionnaire and distinguished into current,
past, and never smokers. The glomerular ﬁltration rate (GFR) was estimated by the
abbreviated modiﬁcation of diet in renal disease (MDRD) equation as recommended
by the National Kidney Foundation [21,22]. A history of myocardial infarction was
deﬁned as a self-reported myocardial infarction that was conﬁrmed by hospital ad-
mission or the presence of a myocardial infarction on the ECG [23]. Prevalent heart
failure was assessed using a validated score based on the deﬁnition of heart failure
by the European Society of Cardiology [24,25]. Prevalent diabetes mellitus was de-
ﬁned as the use of anti-diabetic medication or a pre- or post-load serum glucose
level of N11.0 mmol/l. P-wave duration at baseline of the study was determined
using MEANS, which determines common P-wave onsets and offsets for all 12
leads together on one representative averaged beat, with the use of thresholding
techniques [18].(ms)
eGFR
(ml/min/1.73 m2)
78.0(16.9) 75.8(15.6) 78.2(16.8) 53.4(21.2)⁎
Serum magnesium
(mmol/l)
0.81(0.09) 0.78(0.08) 0.81(0.09) 0.84(0.09)⁎
Values are number of participants (%) or means (SD).
Abbreviations: ACE, Angiotensin converting enzyme; BMI, Bodymass index; DBP, diastolic
blood pressure; eGFR, estimated Glomerular Filtration Rate; HDL, high-density
lipoprotein; SBP, systolic blood pressure.
⁎ p b 0.05, compared to normokalemia, adjusted for age and sex.2.5. Vital status
Information on vital status was obtained on a weekly basis from the Central Register
of Population of the municipality of Rotterdam, from collaborating general practitioners,
and by collecting information during follow-up examination rounds. For the participants
for whom information remained missing, the Central Registry of Genealogy of the
Netherlands was consulted. This national institute receives population registry records
of all inhabitants of the Netherlands who have died.2.6. Population for analysis
Serum potassium levels were assessed at baseline in 5210 participants of the
Rotterdam Study. Participants with prevalent atrial ﬁbrillation at baseline (n = 275)
or participants without a digitally stored ECG at baseline or with missing information on
atrial ﬁbrillation status were excluded (n = 876). This resulted in a study population of
analysis of 4059 participants. All participants were followed from the baseline date of
blood sampling until the date of incident atrial ﬁbrillation, date of death, loss to follow
up, or the end of follow up (January 1, 2008).
2.7. Statistical analysis
Baseline characteristics were obtained from all participants. Serum potassium levels
were analyzed in several ways. First, serum potassium was analyzed as a continuous
variable. Second, as the association of serum potassium with cardiovascular outcomes
has previously been shown to be U-shaped [26], participants were categorized and the
median category was used as a reference. Participants were categorized into commonly
used clinically relevant categories of serum potassium: hypokalemia (b3.50 mmol/l),
normokalemia (3.50–5.00 mmol/l), and hyperkalemia (N5.00 mmol/l). Furthermore,
participants were also categorized into quintiles based on the levels of serum potassium.
Weused logistic and linear regression analyses to testwhether the baseline characteristics
were associated with serum potassium levels after adjustment for age and sex. Next,
we assessed the association of the serum levels potassium with risk of incident atrial
ﬁbrillation, using Cox proportional hazards regression. First, we adjusted for age and
sex. Second, we additionally adjusted for the following potential risk factors: systolic
blood pressure, diastolic blood pressure, use of ACE-inhibitors, high-ceiling diuretics,
low-ceiling diuretics, beta-blockers and other blood pressure lowering drugs, body
mass index, total and HDL cholesterol, current smoking, past smoking, estimated glo-
merular ﬁltration rate, history of myocardial infarction, presence of heart failure,
presence of diabetes mellitus, P-wave duration, and serummagnesium levels. Finally,
to test if the association was modiﬁed by the covariables in the model, interaction
terms of the covariables*serum potassium were added separately. If this interaction
term reached statistical signiﬁcance (p-value b 0.05) we stratiﬁed the study popula-
tion according to this covariable. All measures of association are presented with
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version 20.0 (IBM, Armonk, New York, USA).3. Results
3.1. Baseline characteristics of the study population
Baseline characteristics are summarized in Table 1. The population
for analysis consisted of 4059 participants. The mean age of the popula-
tion at baseline was 69.2 years (SD = 8.6) and included 2425 (59.7%)
females. During a mean follow-up of 11.8 years (SD = 5.2), 474 partic-
ipants developed atrial ﬁbrillation. The mean serum potassium level
was 4.10 mmol/l (SD = 0.31), and ranged from 2.40 to 5.51 mmol/l.
Compared to participants with normokalemia, those with hypokalemia
were more likely to be female, to use low-ceiling diuretics or to use
beta-blocking drugs, and were less likely to smoke. Also participants
with hypokalemia had higher systolic and diastolic blood pressure,
lower total cholesterol and had a longer P-wave duration after adjust-
ment for age and sex.Table 3
The association of serum potassium with risk of atrial ﬁbrillation, stratiﬁed analyses.
Model 1a Model 2b
Serum potassium
(mmol/l)
N n(%) HR 95%-CI HR 95%-CI
Use of high ceiling diuretics
No
Hypokalemia
(b3.50)
101 18 (17.8) 1.66 (1.03–2.66) 1.45 (0.88–2.36)
Normokalemia
(3.50–5.00)
3782 429 (11.3) 1 (Ref.) 1 (Ref.)3.2. The association of serum potassium levels with atrial ﬁbrillation
Serum potassium levels were inversely associated with the risk of
atrial ﬁbrillation after adjustment for age and sex, but not in a multivar-
iable adjusted model (HR per SD increment in serum potassium: 0.96,
95%-CI: 0.87–1.05) (Table 2). Participants with hypokalemia were at
higher risk of atrial ﬁbrillation than those with normal values after
adjustment for age and sex (HR: 1.81, 95%CI: 1.17–2.81) (Table 2).
Also in a multivariable adjusted model this association remained statis-
tically signiﬁcant (HR: 1.62, 95%-CI: 1.02–2.55).When analyzed in quin-
tiles, the lowest quintile of serum potassium levels was associated with
a higher risk of atrial ﬁbrillation than themedian (reference) quintile in
a multivariable adjusted model (HR: 1.37, 95%-CI: 1.02–1.84) (Table 2).
In the multivariable adjusted models, also P-wave duration was associ-
ated with the risk of atrial ﬁbrillation (HR per SD increment in P-wave
duration: 1.20, 95%-CI: 1.10–1.31).Table 2
The association of serum potassium with risk of atrial ﬁbrillation.
Model 1a Model 2b
Serum potassium
(mmol/l)
N n(%) HR 95%-CI HR 95%-CI
Continuous, per SD 4059 474 (11.7) 0.91 (0.83–1.00) 0.96 (0.87–1.05)
Categories
Hypokalemia
(b3.50)
108 21 (19.4) 1.81 (1.17–2.81) 1.62 (1.02–2.55)
Normokalemia
(3.50–5.00)
3933 451 (11.5) 1 (Ref.) 1 (Ref.)
Hyperkalemia
(N5.00)
18 2 (11.1) 0.98 (0.24–3.95) 0.96 (0.24–3.91)
Quintiles
Q1. (2.40–3.85) 820 122 (14.9) 1.61 (1.21–2.14) 1.37 (1.02–1.83)
Q2. (3.86–4.00) 826 79 (9.6) 0.97 (0.71–1.33) 0.95 (0.69–1.30)
Q3. (4.01–4.16) 779 77 (9.9) 1 (Ref.) 1 (Ref.)
Q4. (4.17–4.32) 831 92 (11.1) 1.11 (0.82–1.51) 1.12 (0.83–1.52)
Q5. (4.33–5.51) 803 104 (13.0) 1.27 (0.94–1.70) 1.24 (0.92–1.68)
Notes:
Abbreviations: HR; Hazard rate ratio, N; total number of participants, n; number of those
that developed atrial ﬁbrillation during follow up (% of N).
a Adjusted for age and sex.
b Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, use of ACE
inhibitors, low-ceiling diuretics, high ceiling diuretics, beta blockers and other blood pres-
sure lowering drugs, body mass index, total and HDL cholesterol, current smoking, past
smoking, history of myocardial infarction, presence of heart failure, presence of diabetes,
estimated glomerular ﬁltration rate, P-wave duration, serummagnesium.3.3. Factors modifying the association of serum potassium levels with
atrial ﬁbrillation
The additional interaction terms of: use of high-ceiling diuretics*
hypokalemia and a history of myocardial infarction*hypokalemia, in
the multivariate model were statistically signiﬁcant (p-value: 0.038
and 0.036 respectively). Subsequent stratiﬁed analyses showed that
especially in participants with a history of myocardial infarction,
participants with hypokalemia were associated with a higher risk
of atrial ﬁbrillation than participants with normokalemia (HR: 3.80,
95%-CI: 1.50–9.63) (Table 3).
4. Discussion
In this study, low levels of serum potassium were associated with a
higher risk of atrialﬁbrillation. This associationwas independent of sev-
eral potential confounders.We found that hypokalemia (b3.50 mmol/l)
was associatedwith an increased risk of atrial ﬁbrillation in comparison
to normokalemia. Also participants in the lowest quintile of serum po-
tassium (b3.85 mmol/l) were associated with a higher risk compared
to the median quintile.
Several studies previously investigated the inﬂuence of potassi-
um in the development of atrial ﬁbrillation. Also in a study among
2402 patients undergoing cardiac surgery, preoperative hypokalemia
(b3.5 mmol/l) was associated with atrial ﬁbrillation compared to
higher levels of atrial ﬁbrillation [5]. A study of 253 patients undergoingHyperkalemia
(N5.00)
16 2 (12.5) 1.07 (0.27–4.32) 1.04 (0.26–4.23)
Yes
Hypokalemia
(b3.50)
7 3 (22.7) 3.90 (1.14–13.32) 2.44 (0.40–15.00)
Normokalemia
(3.50–5.00)
151 22 (15.1) 1 (Ref.) 1 (Ref.)
Hyperkalemia
(N5.00)
2 0 (0) NA (NA) NA (NA)
History of myocardial infarction
No
Hypokalemia
(b3.50)
94 15 (16.0) 1.51 (0.90–2.54) 1.24 (0.73–2.13)
Normokalemia
(3.50–5.00)
3460 375 (10.8) 1 (Ref.) 1 (Ref.)
Hyperkalemia
(N5.00)
15 1 (6.7) 0.60 (0.08–4.28) 0.54 (0.07–3.84)
Yes
Hypokalemia
(b3.50)
14 6 (42.9) 3.36 (1.46–7.76) 3.80 (1.50–9.63)
Normokalemia
(3.50–5.00)
473 76 (16.1) 1 (Ref.) 1 (Ref.)
Hyperkalemia
(N5.00)
3 1 (33.3) 3.37 (0.46–24.58) 2.83 (0.33–24.54)
Notes:
Abbreviations: HR; Hazard rate ratio, N; total number of participants, n; number of those
that developed atrial ﬁbrillation during follow up (% of N).
a Adjusted for age and sex.
b Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, use of ACE
inhibitors, low-ceiling diuretics, high ceiling diuretics, beta blockers and other blood pres-
sure lowering drugs, body mass index, total and HDL cholesterol, current smoking, past
smoking, history of myocardial infarction, presence of heart failure, presence of diabetes,
estimated glomerular ﬁltration rate, P-wave duration, serummagnesium.
5414 B.P. Krijthe et al. / International Journal of Cardiology 168 (2013) 5411–5415cardiac surgery, showed an association between lower serum potas-
sium (b3.9 mmol/l) and an increased risk of atrial ﬁbrillation during
the postoperative period [8]. In one study in 517 patients with an
acute myocardial infarction, hypokalemia was not associated with a
higher risk of atrial ﬁbrillation during hospitalization compared to
normokalemia [6], but these differences in results may be caused
by a lack of power or by differences in populations as patients with
an acute myocardial infarction may not be comparable to the general
population or to a population undergoing cardiac surgery. In addition
we found that especially in participants with a history of myocardial
infarction, low serum potassium was associated with a higher risk of
atrial ﬁbrillation. Although these subgroup analyses were based on
small numbers, this is further supported by other studies that suggest
that especially cardiovascular patients are prone to develop ventricular
arrhythmias or sudden cardiac death in case of low serum potassium
[4]. Finally, we found that the association of low serum potassium
with the risk of atrial ﬁbrillation might be modiﬁed by the use of
high-ceiling diuretics. High-ceiling diuretics can cause hypokalemia,
thereby they might amplify the risk of atrial ﬁbrillation in participants
that are at lower levels of serum potassium. However the mecha-
nisms behind these observed interactions have not been completely
elucidated.
We also found that low serum potassium is associated with an in-
crease in P-wave duration, a marker of atrial conduction time, in our
study population. This has also been shown in a study in haemodialysis
patients [9]. P-wave duration increase is associated with a higher risk of
atrial ﬁbrillation [10–14]. Although in our data prolonged P-wave dura-
tion was associated with a higher risk of atrial ﬁbrillation, this can not
solely explain how low serum potassium leads to an increased risk of
atrial ﬁbrillation as both P-wave duration and low serum potassium
levels were independently associated with the risk of atrial ﬁbrillation
when added simultaneously in one model.
The most likely mechanism through which serum potassium leads
to an increased risk of atrial ﬁbrillation is by the inﬂuence of potassium
on the cell membrane potential. It is proposed that a low serum potas-
sium level causes cellular hyperpolarity, increases resting potential
and hastens depolarization [27]. However, no conclusions on causality
can be drawn from our results. It can not be excluded that a low
serum potassium level is a marker of underlying conditions which
predispose to atrial ﬁbrillation.
4.1. Strengths and limitations
Strengths of this study are its population-based design, with
follow-up up to 18 years. This study included extensive information
on clinical details and multiple covariables. The study is limited in
that wewere not able to distinguish between paroxysmal and persis-
tent atrial ﬁbrillation. Also as atrial ﬁbrillation may occur without
symptoms, false-negativemisclassiﬁcationmayhave occurred. However
we used three different methods for the case gathering and assessment,
and included every clinically recognized case from two different sources
of medical records. In addition, we included repeated screening ECG
assessments of the study population at the research centre. Moreover,
any false-negative misclassiﬁcation is likely to be random and therefore
will have led to an underestimation of the true risk estimate. Our study is
limited to one baseline assessment of serum potassium. Also our strati-
ﬁed analyses were based on small numbers and results should therefore
be interpreted cautiously.
4.2. Conclusions
This study with extensive follow-up showed that low serum po-
tassium levels are associated with higher risk of atrial ﬁbrillation.
These results were obtained in the general population, and were in-
dependent of several potential confounders. The proportion of cases
due to low serum potassium may be low but as serum potassium iseasily and frequently obtained this ﬁnding is still relevant at a popu-
lation level, also because atrial ﬁbrillation is relatively common
and may have serious consequences such as stroke. Further studies
with repeatedly measured serum potassium and the risk of atrial
ﬁbrillation would be interesting.
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